{"drugs":["Beyaz","Drospirenone\/Ethinyl Estradiol\/Levomefolate Calcium and Levomefolate Calcium","Safyral"],"mono":{"0":{"id":"930582-s-0","title":"Generic Names","mono":"Drospirenone\/Ethinyl Estradiol\/Levomefolate Calcium and Levomefolate Calcium"},"1":{"id":"930582-s-1","title":"Dosing and Indications","sub":[{"id":"930582-s-1-4","title":"Adult Dosing","mono":"<ul><li>nonhormonal back-up contraception should be used if the patient initiates therapy later than the first day of menstruation or if she has intercourse in the 7 days after missing pills<\/li><li>therapy should not be considered effective as a contraceptive until after the first 7 consecutive days of product administration<\/li><li><b>Acne vulgaris - Contraception:<\/b> Beyaz(R) (drosperinone 3 mg\/ethinyl estradiol 0.02 mg\/levomefolate calcium 0.451 mg and levomefolate calcium 0.451 mg), take 1 pink tablet ORALLY every day for 24 consecutive days followed by 1 orange (inert) tablet daily for 4 days per menstrual cycle<\/li><li><b>Acne vulgaris - Contraception:<\/b> begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Acne vulgaris - Contraception:<\/b> begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule; take pink tablet on the day after the last light orange tablet regardless of menstrual period status<\/li><li><b>Acne vulgaris - Contraception:<\/b> therapy may be initiated 4 weeks postpartum in nonlactating mothers or 4 weeks after a second trimester abortion<\/li><li><b>Contraception:<\/b> Beyaz(R) (drosperinone 3 mg\/ethinyl estradiol 0.02 mg\/levomefolate calcium 0.451 mg and levomefolate calcium 0.451 mg), take 1 pink tablet ORALLY every day for 24 consecutive days followed by 1 orange (inert) tablet daily for 4 days per menstrual cycle<\/li><li><b>Contraception:<\/b> Safyral(TM) (drosperinone 3 mg\/ethinyl estradiol 0.03 mg\/levomefolate calcium 0.451 mg and levomefolate calcium 0.451 mg), take 1 orange tablet ORALLY every day for 21 consecutive days followed by 1 light orange (inert) tablet daily for 7 days per menstrual cycle<\/li><li><b>Contraception:<\/b> begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Contraception:<\/b> begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule<\/li><li><b>Contraception:<\/b> therapy may be initiated 4 weeks postpartum in nonlactating mothers or 4 weeks after a second trimester abortion<\/li><li><b>Contraception, Raise Folate Levels:<\/b> Beyaz(R) (drosperinone 3 mg\/ethinyl estradiol 0.02 mg\/levomefolate calcium 0.451 mg and levomefolate calcium 0.451 mg), take 1 pink tablet ORALLY every day for 24 consecutive days followed by 1 orange (inert) tablet daily for 4 days per menstrual cycle<\/li><li><b>Contraception, Raise Folate Levels:<\/b> Safyral(TM) (drosperinone 3 mg\/ethinyl estradiol 0.03 mg\/levomefolate calcium 0.451 mg and levomefolate calcium 0.451 mg), take 1 orange tablet ORALLY every day for 21 consecutive days followed by 1 light orange (inert) tablet daily for 7 days per menstrual cycle<\/li><li><b>Contraception, Raise Folate Levels:<\/b> begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Contraception, Raise Folate Levels:<\/b> begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule;<\/li><li><b>Contraception, Raise Folate Levels:<\/b> therapy may be initiated 4 weeks postpartum in nonlactating mothers or 4 weeks after a second trimester abortion<\/li><li><b>Contraception - Premenstrual dysphoric disorder:<\/b> Beyaz(R) (drosperinone 3 mg\/ethinyl estradiol 0.02 mg\/levomefolate calcium 0.451 mg and levomefolate calcium 0.451 mg), take 1 pink tablet ORALLY every day for 24 consecutive days followed by 1 orange (inert) tablet daily for 4 days per menstrual cycle<\/li><li><b>Contraception - Premenstrual dysphoric disorder:<\/b> begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Contraception - Premenstrual dysphoric disorder:<\/b> begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule; take pink tablet on the day after the last light orange tablet regardless of menstrual period status<\/li><li><b>Contraception - Premenstrual dysphoric disorder:<\/b> therapy may be initiated 4 weeks postpartum in nonlactating mothers or 4 weeks after a second trimester abortion<\/li><\/ul>"},{"id":"930582-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>use of this product before menarche is not indicated<\/li><li><b>Acne vulgaris - Contraception:<\/b> Beyaz(R) (drosperinone 3 mg\/ethinyl estradiol 0.02 mg\/levomefolate calcium 0.451 mg and levomefolate calcium 0.451 mg), (14 years and older) after menarche, take 1 pink tablet ORALLY every day for 24 consecutive days followed by 1 orange (inert) tablet daily for 4 days per menstrual cycle<\/li><li><b>Acne vulgaris - Contraception:<\/b> begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Acne vulgaris - Contraception:<\/b> begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule; take pink tablet on the day after the last light orange tablet regardless of menstrual period status<\/li><li><b>Acne vulgaris - Contraception:<\/b> therapy may be initiated 4 weeks postpartum in nonlactating mothers or 4 weeks after a second trimester abortion<\/li><li><b>Contraception:<\/b> after menarche, same dose as adults<\/li><li><b>Contraception, Raise Folate Levels:<\/b> after menarche, same dose as adults<\/li><li><b>Contraception - Premenstrual dysphoric disorder:<\/b> Beyaz(R) (drosperinone 3 mg\/ethinyl estradiol 0.02 mg\/levomefolate calcium 0.451 mg and levomefolate calcium 0.451 mg), after menarche, take 1 pink tablet ORALLY every day for 24 consecutive days followed by 1 orange (inert) tablet daily for 4 days per menstrual cycle<\/li><li><b>Contraception - Premenstrual dysphoric disorder:<\/b> begin therapy either on the first day of menstrual period or on the first Sunday after the onset of menstruation<\/li><li><b>Contraception - Premenstrual dysphoric disorder:<\/b> begin next and all subsequent 28-day regimens of therapy on the same day of the week as the first regimen began and follow the same schedule; take pink tablet on the day after the last light orange tablet regardless of menstrual period status<\/li><li><b>Contraception - Premenstrual dysphoric disorder:<\/b> therapy may be initiated 4 weeks postpartum in nonlactating mothers or 4 weeks after a second trimester abortion<\/li><\/ul>"},{"id":"930582-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> use contraindicated<\/li><li><b>hepatic impairment:<\/b> use contraindicated<\/li><\/ul>"},{"id":"930582-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acne vulgaris - Contraception<\/li><li>Contraception<\/li><li>Contraception, Raise Folate Levels<\/li><li>Contraception - Premenstrual dysphoric disorder<\/li><\/ul>"}]},"2":{"id":"930582-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.<br\/>"},"3":{"id":"930582-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930582-s-3-9","title":"Contraindications","mono":"<ul><li>adrenal insufficiency<\/li><li>breast cancer or other estrogen or progestin-sensitive cancer, current or past history<\/li><li>cerebrovascular disease<\/li><li>coronary artery disease<\/li><li>deep vein thrombosis or pulmonary embolism, current or past history<\/li><li>diabetes mellitus with vascular disease<\/li><li>headaches with focal neurological symptoms or migraine headaches with or without aura if over age 35 years<\/li><li>hepatic tumors, benign or malignant (adenomas or carcinomas)<\/li><li>hepatic disease<\/li><li>hypercoagulopathies, inherited or acquired<\/li><li>hypertension, uncontrolled<\/li><li>pregnancy<\/li><li>renal impairment<\/li><li>smoking and over age 35 years<\/li><li>thrombogenic valvular or thrombogenic rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease or atrial fibrillation)<\/li><li>uterine bleeding, undiagnosed, abnormal<\/li><\/ul>"},{"id":"930582-s-3-10","title":"Precautions","mono":"<ul><li>cigarette smoking, especially with high number of cigarettes smoked and increased age (over 35 years); increased risk of cardiovascular events including myocardial infarction<\/li><li>advancing age, especially over 35 years; increased risk of cerebrovascular and cardiovascular events<\/li><li>amenorrhea or oligomenorrhea may occur after discontinuation, especially if preexisting<\/li><li>arterial or venous thrombotic events (VTE) may occur; possible increased risk of VTE with drospirenone-containing oral contraceptives combined with 0.03 mg of ethinyl estradiol over levonorgestrel or some other progestins; discontinue use if arterial or VTE occurs<\/li><li>cerebrovascular events (thrombotic and hemorrhagic stroke) may occur; increased risk over age 35 years and with hypertensive women who smoke or have underlying risk factors<\/li><li>chloasma may occur, especially with history of chloasma gravidarum<\/li><li>depression may be exacerbated; discontinuation recommended for serious depression<\/li><li>diabetes (including prediabetic women); dose-related decrease in glucose tolerance may occur; monitoring recommended<\/li><li>dyslipidemia, uncontrolled; may exacerbate; consider alternative contraception<\/li><li>gallbladder disease may occur<\/li><li>headaches, new-onset and recurrent, persistent, or severe; evaluate and discontinue if necessary<\/li><li>hepatic adenoma or hepatocellular carcinoma may occur; increased risk associated with long-term use<\/li><li>hereditary angioedema; may induce or exacerbate symptoms<\/li><li>hyperkalemia may occur in high-risk patients; monitoring recommended when used concomitantly with daily maintenance medications known to increase serum potassium (ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDs)<\/li><li>hypertension may occur, especially in older women with extended duration of use; monitoring recommended; discontinue if necessary<\/li><li>hypertensive women who also smoke; increased risk of cerebrovascular events<\/li><li>hypertriglyceridemia, or family history; increased risk of pancreatitis<\/li><li>jaundice may occur; discontinue use<\/li><li>migraine headaches that increase in frequency or severity; evaluate and discontinue if necessary<\/li><li>postpartum period; increased risk of thromboembolism, do not initiate therapy earlier than 4 weeks following delivery<\/li><li>pregnancy-related cholestasis, past history, or cholestasis with prior hormonal contraceptive use; increased risk for recurrence<\/li><li>retinal vein thrombosis has occurred; discontinue use if unexplained ocular symptoms emerge (eg, loss of vision, diplopia, proptosis, papilledema, retinal vascular lesions)<\/li><li>surgery, major or elective; increased risk of thromboembolism; discontinue use 4 weeks before and through 2 weeks after procedure<\/li><li>vaginal bleeding abnormalities, including breakthrough bleeding and spotting may occur; rule out malignancy, other pathology, or pregnancy<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930582-s-3-11","title":"Pregnancy Category","mono":"Fetal risk has been demonstrated. (TH)<br\/>"},{"id":"930582-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930582-s-4","title":"Drug Interactions","sub":[{"id":"930582-s-4-13","title":"Contraindicated","mono":"<ul><li>Boceprevir (probable)<\/li><li>Dasabuvir (theoretical)<\/li><li>Ombitasvir (established)<\/li><li>Paritaprevir (established)<\/li><li>Ritonavir (theoretical)<\/li><li>Tranexamic Acid (probable)<\/li><\/ul>"},{"id":"930582-s-4-14","title":"Major","mono":"<ul><li>Anagrelide (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Felbamate (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Paclitaxel Protein-Bound (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pirfenidone (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"930582-s-4-15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Clarithromycin (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Efavirenz (probable)<\/li><li>Eslicarbazepine Acetate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Ginseng (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Roflumilast (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Tipranavir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Valdecoxib (probable)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},"5":{"id":"930582-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Weight increased<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain, Nausea, Vomiting<\/li><li><b>Neurologic:<\/b>Headache<\/li><li><b>Psychiatric:<\/b>Depression, Irritability, Labile affect<\/li><li><b>Reproductive:<\/b>Break-through bleeding, Breast tenderness, Disorder of menstruation, Pain of breast, Reduced libido<\/li><li><b>Other:<\/b>Fatigue<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Arterial thromboembolism, Deep venous thrombosis, Hypertension, Myocardial infarction<\/li><li><b>Endocrine metabolic:<\/b>Hyperkalemia, Impaired glucose tolerance<\/li><li><b>Gastrointestinal:<\/b>Disorder of gallbladder, Pancreatitis<\/li><li><b>Hematologic:<\/b>Thromboembolic disorder, Venous thromboembolism<\/li><li><b>Hepatic:<\/b>Chloasma, Cholestasis, Liver function tests abnormal, Neoplasm of liver<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Hemorrhagic cerebral infarction, Migraine, Thrombotic stroke<\/li><li><b>Ophthalmic:<\/b>Thrombosis of retinal vein<\/li><li><b>Reproductive:<\/b>Amenorrhea, Dysplasia of cervix, Oligomenorrhea<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><\/ul>"},"6":{"id":"930582-s-6","title":"Drug Name Info","sub":[{"id":"930582-s-6-17","title":"US Trade Names","mono":"<ul><li>Beyaz<\/li><li>Safyral<\/li><\/ul>"},{"id":"930582-s-6-18","title":"Synonyms","mono":"Estrogen\/Progestin\/Folate Combination<br\/>"},{"id":"930582-s-6-19","title":"Class","mono":"<ul><li>Contraceptive<\/li><li>Contraceptive Combination<\/li><li>Estrogen<\/li><li>Progestin<\/li><li>Vitamin B (class)<\/li><\/ul>"},{"id":"930582-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}]},"7":{"id":"930582-s-7","title":"Mechanism Of Action","mono":"Drospirenone\/ethinyl estradiol\/levomefolate calcium is an combination oral contraceptive (COC) that works primarily by suppressing ovulation. Additionally, COC agents cause cervical mucus changes that block sperm penetration and endometrial changes that reduce the chance of implantation. Levomefolate calcium is a synthetic calcium salt of L-5-methyltetrahydrofolate, a metabolite of vitamin B9, that increases the folate pool in the body. Although the exact mechanism of action in acne is unknown, drospirenone and ethinyl estradiol increase sex hormone binding globulin and decrease free testosterone, which may play a role.<br\/>"},"8":{"id":"930582-s-8","title":"Pharmacokinetics","sub":[{"id":"930582-s-8-23","title":"Absorption","mono":"<ul><li>Drospirenone, Tmax, Oral: 1 to 2 hours<\/li><li>Drospirenone, Bioavailability, Oral: 76%<\/li><li>Drospirenone, Effect of food: slower rate of absorption, reduced Cmax by 40%, but no effect on extent of absorption<\/li><li>Ethinyl estradiol, Tmax, Oral: 1 to 2 hours<\/li><li>Ethinyl estradiol, Bioavailability, Oral: 40%<\/li><li>Ethinyl estradiol, Effect of food: slower rate of absorption, reduced Cmax by 40%, and reduced extent of absorption by 20%<\/li><li>Levomefolate calcium, Tmax, Oral: 0.5 to 1.5 hours<\/li><\/ul>"},{"id":"930582-s-8-24","title":"Distribution","mono":"<ul><li>Drospirenone, Vd: 4 L\/kg<\/li><li>Drospirenone, Protein binding: 97%<\/li><li>Ethinyl estradiol, Vd: 4 to 5 L\/kg<\/li><li>Ethinyl estradiol, Protein binding, Albumin: 98.5%<\/li><\/ul>"},{"id":"930582-s-8-25","title":"Metabolism","mono":"<ul><li>Drospirenone, Liver: minor extent via CYP3A4<\/li><li>Ethinyl estradiol, Liver: unknown extent via CYP3A4<\/li><li>Ethinyl estradiol, Small bowel mucosa: unknown extent<\/li><li>Ethinyl estradiol, 2-hydroxy metabolite: major<\/li><\/ul>"},{"id":"930582-s-8-26","title":"Excretion","mono":"<ul><li>Drospirenone, Fecal: trace amounts as unchanged drug; 17% to 20% excreted as glucuronide and sulfate conjugates<\/li><li>Drospirenone, Renal: trace amounts as unchanged drug; 38% to 47% excreted as glucuronide and sulfate conjugates<\/li><li>Ethinyl estradiol, Fecal: none as unchanged drug; excreted as glucuronide and sulfate conjugates<\/li><li>Ethinyl estradiol, Renal: none as unchanged drug; excreted as glucuronide and sulfate conjugates<\/li><li>Levomefolate calcium, Fecal: excreted through a biphasic kinetics process<\/li><li>Levomefolate calcium, Renal: excreted as intact folates and catabolic products<\/li><\/ul>"},{"id":"930582-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Drospirenone: 30 hours<\/li><li>Ethinyl estradiol: 24 hours<\/li><li>Levomefolate calcium: 4 to 5 hours<\/li><\/ul>"}]},"9":{"id":"930582-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>take exactly as directed and at the same time each day, preferably after the evening meal or at bedtime <br\/>"},"10":{"id":"930582-s-10","title":"Monitoring","mono":"<ul><li>acne: improvement in symptoms of moderate acne is indicative of efficacy<\/li><li>premenstrual dysphoric disorder (PMDD): improvement in symptoms of PMDD is indicative of efficacy<\/li><li>annual physical; including blood pressure<\/li><li>blood pressure; in women with controlled hypertension<\/li><li>fasting blood glucose; in diabetic and prediabetic women<\/li><\/ul>"},"12":{"id":"930582-s-12","title":"Toxicology","sub":[{"id":"930582-s-12-31","title":"Clinical Effects","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>USES: To suppress the follicle-stimulating hormone luteinizing hormone sequence from the anterior pituitary, resulting in the suppression of ovulation and production of mucus that is less acceptable to spermatozoa. PHARMACOLOGY: An oral contraceptive acts by suppression of gonadotropins. TOXICOLOGY: There are no significant toxic effects from overdose. OVERDOSE: Abdominal pain, nausea, vomiting, headaches, breast tenderness, dysmenorrhea, arterial thromboembolism, hypertension, venous thrombosis, pulmonary embolus, cerebral thrombosis. ADVERSE EFFECTS: Nausea and vomiting with iron containing contraceptives in children, otherwise asymptomatic. <br\/>"},{"id":"930582-s-12-32","title":"Treatment","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/><ul><li>Support:                       MANAGEMENT OF MILD TO MODERATE TOXICITY: The vast majority of oral contraceptive overdoses require only supportive care. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is not expected in single substance oral contraceptive ingestion.<\/li><li>Decontamination:                       There is no need for GI decontamination.<\/li><li>Airway management:                       Patients with single substance oral contraceptive ingestion will not require airway management.<\/li><li>Antidote:                       None.<\/li><li>Enhanced elimination procedure:                       Hemodialysis and hemoperfusion are not of value.<\/li><li>Monitoring of patient:                       Concentrations of the hormones in oral contraceptives are not clinically useful. No routine laboratory studies are needed in most patients.<\/li><li>Patient disposition:                       HOME CRITERIA: Patients with inadvertent ingestions can be managed at home. If oral contraceptives containing iron are ingested, asymptomatic patients ingesting less than 40 mg\/kg elemental iron can be managed at home. OBSERVATION CRITERIA: The following patients should be sent to a healthcare facility for evaluation: Patients with self-harm ingestions; patients ingesting iron-containing oral contraceptives at a dose of more than 40 mg\/kg elemental iron or who have symptoms (nausea, vomiting, or other gastrointestinal complaints). ADMISSION CRITERIA: Patients with pure oral contraceptive overdoses do not need admission. Children with exposure to iron-containing products should follow the iron guidelines for admission. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients for any additional questions.<\/li><\/ul>"},{"id":"930582-s-12-33","title":"Range of Toxicity","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>TOXICITY: A human toxic dose has not been established. Significant toxicity has not been reported after overdose. THERAPEUTIC DOSE: Oral contraceptives are available in various brands, doses, and formulations. <br\/>"}]},"13":{"id":"930582-s-13","title":"Clinical Teaching","mono":"<ul><li>Patients over 35 years of age should not smoke during therapy, as this increases the risk of serious cardiovascular side effects.<\/li><li>Advise patient to practice safe sex. Drug does not prevent disease transmission.<\/li><li>Discuss potential long-term adverse effects of hormone therapy including myocardial infarction, stroke, thrombophlebitis, venous thromboembolism (VTE), dementia, pulmonary embolism, and breast cancer. Inform patient that risk of VTE is greatest after initially starting therapy or restarting therapy after a 4-week or greater pill-free interval.<\/li><li>This drug may cause weight gain, nausea\/vomiting, abdominal pain\/tenderness\/discomfort, headache\/migraine, fatigue, mood changes, menstrual irregularities, or breast pain\/discomfort\/tenderness.<\/li><li>Instruct patient to report signs\/symptoms of serious cardiovascular events, such as myocardial infarction, stroke, venous thrombosis, pulmonary embolism, and retinal vein thrombosis.<\/li><li>Tell patient to report persistent\/recurrent abnormal vaginal bleeding or amenorrhea of 2 or more consecutive cycles.<\/li><li>Patients should report any unexplained partial or complete loss of vision. In addition, patients who wear contact lenses should report visual changes or changes in lens tolerance.<\/li><li>This drug should be taken every day, at the same time each day.<\/li><li>Advise patient to use a non-hormonal backup form of contraception for the first 7 days if a Sunday-start regimen is initiated or if drug is initiated postpartum before menstruation resumes.<\/li><li>Advise patient that certain drugs may cause oral contraceptives to be less effective and backup contraception may be necessary. Consult healthcare professional prior to new drug use.<\/li><li>Review the procedure for handling missed doses. The patient should carefully follow missed-dose instructions in order to prevent pregnancy.<\/li><\/ul>"}}}